Browsing: Featured
ESMO 2023: Lung cancer treatment research enters a new era
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs…
ESMO 2023: Advances in gynaecological cancer research could change the treatment landscape
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new…
ESMO 2023: Better use of existing drugs increases cervical cancer survival and reduces recurrence
The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre,…
ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup…
ESMO 2023: Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy…
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the…
Learning more about how cancer affects stroke risk
Patients with a previous or current cancer diagnosis are more likely to have a stroke…
ESMO 2023: The potential of AI to improve cancer care is only going to grow
Artificial intelligence (AI) has made a grand entrance into the public debate this year, but…
ESMO 2023: Air pollution and breast cancer risk – a link that calls for political action
Women living and working in places with higher levels of fine particle air pollution are…